- Home
- Publications
- Publication Search
- Publication Details
Title
VEGF inhibition in urothelial cancer: the past, present and future
Authors
Keywords
-
Journal
WORLD JOURNAL OF UROLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-02
DOI
10.1007/s00345-020-03213-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.
- (2019) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- (2019) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current and Emerging Therapies for First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma
- (2018) Michael B. Atkins et al. CANCER TREATMENT REVIEWS
- Docetaxel with or without ramucirumab after immune checkpoint inhibition in platinum-refractory metastatic urothelial carcinoma (mUC): Prespecified subgroup analysis from the phase 3 RANGE trial.
- (2018) Alexandra Drakaki et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
- (2018) Manish R Patel et al. LANCET ONCOLOGY
- Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma
- (2018) Joaquim Bellmunt et al. BRITISH JOURNAL OF CANCER
- Ramucirumab (RAM) exposure-response (ER) relationship in RANGE, a randomized phase III trial of docetaxel (DOC) with or without RAM in advanced urothelial carcinoma (UC) patients (pts) who progressed on or after platinum therapy.
- (2018) Ronald De Wit et al. JOURNAL OF CLINICAL ONCOLOGY
- Global Burden of Urologic Cancers, 1990–2013
- (2017) Geolani W. Dy et al. EUROPEAN UROLOGY
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
- (2017) Daniel P Petrylak et al. LANCET
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer
- (2016) Sujata Narayanan et al. Clinical Genitourinary Cancer
- TOUCAN: A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin.
- (2016) Robert J. Jones et al. JOURNAL OF CLINICAL ONCOLOGY
- Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial
- (2016) Daniel P. Petrylak et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Incorporating VEGF-targeted therapy in advanced urothelial cancer
- (2016) Sujata Narayanan et al. Therapeutic Advances in Medical Oncology
- Evolution of ramucirumab in the treatment of cancer – A review of literature
- (2016) A Vennepureddy et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Contemporary Occupational Carcinogen Exposure and Bladder Cancer
- (2015) Marcus G. K. Cumberbatch et al. JAMA Oncology
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer
- (2013) Roberto Pili et al. Clinical Genitourinary Cancer
- Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer
- (2013) Arjun V. Balar et al. JOURNAL OF CLINICAL ONCOLOGY
- Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study
- (2013) Yoo-Joung Ko et al. LANCET ONCOLOGY
- Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
- (2012) Andrea Necchi et al. LANCET ONCOLOGY
- Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity
- (2011) J. Bellmunt et al. ANNALS OF ONCOLOGY
- Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75
- (2011) Noah M. Hahn et al. JOURNAL OF CLINICAL ONCOLOGY
- Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
- (2011) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Ethnic Differences in Bladder Cancer Survival
- (2011) David S. Yee et al. UROLOGY
- Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial
- (2010) Przemyslaw Twardowski et al. UROLOGY
- Phase 2 trial of sorafenib in patients with advanced urothelial cancer
- (2009) Robert Dreicer et al. CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now